Replies to post #70692 on Ayala Pharmaceuticals Inc (ADXS)

[ignatiusrielly35]

Let’s take the rough metric of 6x annual sales per year times the expected market life. Subtract the cost of development. Discount it for risk of non-approval and net present value. $50m would mean projected discounted projected annual sales of next to nothing. Ridiculous.